James E. Dillard, III net worth and biography

James Dillard, III Biography and Net Worth

EVP of Perrigo

James E. Dillard III was named Executive Vice President and President Consumer Healthcare Americas in October 2021. Mr. Dillard served as Perrigo Executive Vice President and Chief Scientific Officer since 2019. Mr. Dillard joined Perrigo from Altria Group, Inc., where he served as Senior Vice President, Research, Development and Sciences and Chief Innovation Officer. During his tenure with Altria Group, Mr. Dillard led the creation of the Regulatory Affairs function in 2009 and also served as Chief Innovation Officer for Altria Client Services and Senior Vice President of Research, Development & Regulatory Affairs, for Altria Group. He held science and technology leadership roles with U. S. Smokeless Tobacco Company (USSTC), an Altria Group Inc. operating company, from 2001 to 2009. Mr. Dillard worked for the U.S. Food and Drug Administration (FDA) between 1987 and 2001, as Director of the Division of Cardiovascular and Respiratory Devices, as well as in various leadership roles in the Center for Devices and Radiological Health and the Office of Device Evaluation.

What is James E. Dillard, III's net worth?: The estimated net worth of James E. Dillard, III is at least $647,097.50 as of March 10th, 2023. Mr. Dillard, III owns 25,130 shares of Perrigo stock worth more than $647,098 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Dillard, III may own. Learn More about James E. Dillard, III's net worth.
How do I contact James E. Dillard, III?: The corporate mailing address for Mr. Dillard, III and other Perrigo executives is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. Perrigo can also be reached via phone at (531) 709-4000 and via email at [email protected]. Learn More on James E. Dillard, III's contact information.
Has James E. Dillard, III been buying or selling shares of Perrigo?: James E. Dillard, III has not been actively trading shares of Perrigo in the last ninety days. Most recently, James E. Dillard III sold 9,000 shares of the business's stock in a transaction on Friday, March 10th. The shares were sold at an average price of $35.70, for a transaction totalling $321,300.00. Following the completion of the sale, the executive vice president now directly owns 25,130 shares of the company's stock, valued at $897,141. Learn More on James E. Dillard, III's trading history.
Who are Perrigo's active insiders?: Perrigo's insider roster includes Bradley Alford (Director), Svend Andersen (EVP), Eduardo Bezerra (CFO), Rolf Classon (Director), James Dillard, III (EVP), Thomas Farrington (EVP), Alison Ives (EVP), Ronald Janish (EVP), Murray Kessler (CEO), Todd Kingma (VP), Patrick Lockwood-Taylor (President, CEO & Director), Geoffrey Parker (Director), Grainne Quinn (EVP), Theodore Samuels, II (Director), Raymond Silcock (CFO), Richard Sorota (EVP), and Robert Willis (EVP). Learn More on Perrigo's active insiders.
Are insiders buying or selling shares of Perrigo?: During the last twelve months, Perrigo insiders bought shares 4 times. They purchased a total of 18,990 shares worth more than $503,127.40. During the last twelve months, insiders at the sold shares 4 times. They sold a total of 67,852 shares worth more than $1,909,464.66. The most recent insider tranaction occured on December, 9th when Director Jeffrey B Kindler sold 17,598 shares worth more than $497,495.46. Insiders at Perrigo own 0.7% of the company. Learn More about insider trades at Perrigo.
Information on this page was last updated on 12/9/2024.

James E. Dillard, III Insider Trading History at Perrigo

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/10/2023	Sell	9,000	$35.70	$321,300.00	25,130

James E. Dillard, III Buying and Selling Activity at Perrigo

Perrigo Company Overview

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Today's Range

Now: $25.75

$25.55

$26.13

50 Day Range

MA: $26.69

$24.18

$28.91

2 Week Range

Now: $25.75

$23.89

$34.60

Volume

2,571,510 shs

Average Volume

1,601,156 shs

Market Capitalization

$3.51 billion

P/E Ratio

N/A

Dividend Yield

4.34%

Beta

0.52

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol